OBJECTIVES: Golimumab is the first and only monthly subcutaneous fully human anti-TNF approved in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study evaluated co morbidities and pre-index biologic use among patients who received golimumab in the GE Centricity® electronic medical records (EMR) database. METHODS: Longitudinal EMR data were collected from outpatient practices in the United States. It contains clinical information on over 15 million patients through September 2010. Patients were selected based on the following criteria: ≥1ICD-9 diagnosis of RA, PsA, or AS; ≥18 years of age at the time of the first diagnosis; data 6-months prior and 3-months after a prescription record of the first biologic, and at least one prescription record for golimumab. Biologic experience was defined as use of a biologic within 6 months prior to the first golimumab record.  RESULTS: A total of 153 [118 (RA); 20 (PsA); 15 (AS)] patients receiving golimumab were identified as meeting all the inclusion criteria. The mean age was 49 years and 75% were female; 101 (66%) patients were biologic-experienced, and 52 (34%) were biologic-naïve before initiating golimumab. A higher percentage of female patients were in the bio-experienced category (70% vs. 55%). Osteoarthritis (27%), hypertension (24%), dyslipidemia (17%), and depressive disorders (14%) were the most common comorbidities prior to the start of golimumab. A higher rate of depressive disorder was observed in the biologic-experienced group. Baseline mean C-reactive protein test values were also higher in the biologic-experienced group (3.69 vs. 0.97). Biologic-experienced patients on golimumab were switched mostly from adalimumab (n=42) and etanercept (n=25). CONCLUSIONS: In this longitudinal EMR, patients receiving golimumab were more likely to have prior biologic experience. Biologic-experienced patients appeared to have higher C-reactive protein test values and greater rates of depressive disorders than their biologic-naïve counterparts.